Mannkind Corp
MNKD
Market Cap$1.39B
Close$
$4.94
4.6% upside
Current Fair Value
4.6% upsideUndervalued by 4.6% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $1.39 Billion |
|---|---|
| Enterprise Value | $1.40 Billion |
| Dividend Yield | $0 (0%) |
| Earnings per Share | $0.1 |
| Beta | 1.14 |
| Outstanding Shares | 279,191,000 |
Return
| Return on Equity | - |
|---|---|
| Return on Assets | - |
| Return on Invested Capital | - |
Valuation & Multiples
| P/E Ratio | 46.15 |
|---|---|
| PEG | 8.08 |
| Price to Sales | - |
| Price to Book Ratio | -4.72 |
| Enterprise Value to Revenue | 6.45 |
| Enterprise Value to EBIT | 25.54 |
| Enterprise Value to Net Income | 64 |
| Total Debt to Enterprise | 0.04 |
| Debt to Equity | -0.76 |
Revenue Sources
No data
Insider Trades
ESG Score
No data
About Mannkind Corp
233 employees
CEO: Michael Castagna MannKind Corporation focuses on the development and commercialization of inhaled therapeutic products for patients with endocrine and orphan lung diseases. MannKind is currently commercializing Afrezza® (insulin human) Inhalation Powder,...